Shares in Vaxcyte have rocketed on the revelation of phase 3 trial data for its pneumococcal vaccine (PCV) candidate VAX-31, ...

Eli Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA in its first frontline indication for chronic ...

Marcus Evans will host the PharmaMarketing Summit from 21 to 22 January 2027 at the prestigious Four Seasons Hotel Westlake ...

Isao Teshirogi, Shionogi's chief executive. Shionogi has reached a $2 billion agreement to buy Anglo-US biotech IntraBio and ...

The 2026 Nobel Prize in Physiology or Medicine has been awarded jointly to three scientists – Karl Deisseroth, Peter Hegemann ...

If it reaches the market, profits on lixudebart sales will be shared 55% to CSL and 45% to Alentis. Under the terms of the ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial ...

Bayer has joined the ranks of pharma multinationals planning major new facility investments in the US, revealing a plan to ...

In the largest venture financing round this week, Varda Space Industries closed a $251 million financing round to help fund ...

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a partnership – worth up to $8 billion – that spans ...

AbbVie's long-acting anti-IL-13 antibody zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – ...